Introduction
Timely and accurate diagnosis of bacterial infections is essential for successful patient treatment. In addition to conventional analyses of blood, urine, or tissue biopsy, diagnosis is often made with non-invasive imaging modalities i.e. anatomical or functional. [1] [2] [3] The development of bacteria-specific radiotracers for infection is therefore of considerable interest to improve diagnostic accuracy and thereby patient treatment. The field of developing bacteria-specific radiotracers, targeting unique bacterial characteristics, has been explored during the past decades; 1, 3, 6 among the most extensively researched tracers are the radiolabelled antibiotic ciprofloxacin and the antimicrobial peptide ubiquicidin. [7] [8] [9] [10] [11] [12] [13] Recently, the development of bacteria-specific tracers, e.g. 2-[ 18 F]-fluorodeoxysorbitol and 18 F-labelled maltohexaose, have exploited the differences in sugar metabolism of bacteria and human cells with promising results. 14, 15 In most cases, however, it is unknown if or to what extent the developed bacteria-specific imaging probes bind to bacteria aggregated in biofilms in vivo. 3 S. aureus is a major cause of soft tissue, endovascular, bone and post-surgical infections, and is often associated with abscess and biofilm formation. 16, 17 We have earlier reported the identification of the dodecapeptide A9 by phage-display selection against S. aureus biofilm,
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as well as the gallium-68 labelling, and initial biological evaluation of the 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide DOTA-K-A9
(FigureA) as a potentially bacteria-specific PET-tracer. 18 The purpose of this study was to further investigate if the [ 68 Ga]Ga-DOTA-K-A9 was able to differentiate between infected and aseptic inflamed tissues using µPET/MRI and compare it to 
Experimental

Materials
All chemicals were of analytical grade or better and used without further purification. The main suppliers were Sigma-Aldrich (Brøndby, Denmark) and Merck (Darmstadt, Germany).
Aqueous solutions for high performance liquid chromatography (HPLC) analysis were prepared with deionised distilled water (Milli-Q water system; Millipore, Aarhus, Denmark).
In all other aqueous solutions water for injection (Danish Capital Region Pharmacy) was applied. The DOTA-K-A9 peptide for gallium-68 labelling and the fluorescence analogue of the peptide TAMRA-K-A9 were custom synthesised by Pepscan (Lelystad, The Netherlands).
The membrane-impermeable DNA-binding stain TOTO®-1 was bought from Thermo Fisher (Naerum, Denmark 19 . Purity analyses of the radiolabelled compounds were performed using reversed-phase HPLC on an Ultimate 3000 system from Dionex (Hvidovre, Denmark) and thin-layer chromatography (TLC) on a PET miniGita* TLC scanner from Raytest (Straubenhardt, Germany). The acetone and ethanol content in the product was analysed by Gas Chromatography (GC) on a Clarus 480 GC from Perkin Elmer (Skovlunde, Denmark), pH-values were measured applying a PH M220 pH-meter from Radiometer Analytical (Villeurbanne, France), and the radioactivity of the products was determined by a VDC-405 dose calibrator from Veenstra Instruments (Joure, The Netherlands).
The binding selectivity of [ 68 Ga]Ga-DOTA-K-A9 was evaluated by µPET/MRI on mice using an integrated Mediso NanoScan® PET/MRI system from Mediso Medical Imaging Systems (Budapest, Hungary).
Bacteria
The different bacteria used in the study are listed in Table 1 . The S. aureus isolate originating from a clinical prosthesis infection, which was used to prepare the biofilm applied in the preceding phage-display selection of the A9 peptide, 18 was also used in both the murine SC infection model and in vitro evaluation of TAMRA-K-A9. The bacteria were grown overnight from a single colony in tryptic soy broth (TSB) at 37 °C while being gently shaken at 200 rpm on an incubator shaker (IKA KS 4000i control, from VWR). Following overnight incubation, the bacteria suspension was density adjusted according to 600 nm absorbance This article is protected by copyright. All rights reserved.
with TSB (5x 10 7 colony forming unit (CFU)/ml) for the mice inoculation. For the morphological in vitro evaluation, samples of dead bacteria were additionally prepared by immersing a swap in each of the fresh bacteria cultures and subsequently transferring the swaps with bacteria to tubes containing CyMol® (COPAN, Italy) and incubated for 10 min at room temperature, to kill the bacteria. Then the tubes were vortexed shortly, before the solutions (1 ml each) were transferred to new tubes. labelling of the peptide in the reactor. First, the 50% EtOH aq. solution (5 ml) was passed through the C18-light cartridge followed by air (10 ml); second, the cartridge was washed with the 0.1 M HEPES aq. solution (5 ml) and dried again with air (10 ml).
After the 3.5 min labelling reaction, the [ 68 Ga]Ga-DOTA-K-A9 reaction mixture was immediately transferred and trapped on the C18-light cartridge and rinsed with 0.1 M HEPES aq. solution pH 5.2 (2 ml), before it was eluted with 50% EtOH aq. solution (1 ml). The final formulation (9 ml) of the product was achieved by adding isotonic saline (8 ml) . The stability of the [ 68 Ga]Ga-DOTA-K-A9 in the product formulation (pH 5.1 -5.7) was evaluated up to 120 min employing the radio-HPLC setup described in the next section. The product formulation was further diluted prior to the biological testing in mice, to achieve an ethanol content <5 % (v/v).
Quality control
Decay corrected radiochemical yield, and radiochemical purity were determined using radio-TLC and radio-HPLC. 7.1 ± 0.5 min.
In vivo evaluation
Animals
The studies in mice were performed according to the Danish Animal Experimentation Act In this study, C57Bl6/J mice (n = 17, adult, females, 20-22 g) were applied, with the analyses performed on each mouse shown in Table 2 . The mice for the pilot infection study (n = 3)
were purchased from M&B Taconic, while the mice in the main infection and inflammation comparison study came from Janvier Labs. All animals had an acclimatisation period of minimum 7 days at the experimental animal facility. They were housed with a 12 h light/dark cycle and had access to tap water ad libitum and pellet feed.
During the scans the animals were placed on a gantry which regulated the temperature to 37 °C and they were kept lightly anesthetised by isoflourane in an oxygene-medical air mixture
through a mask, while they were removed from anaesthesia between scans. After the last PET scan, the mice were euthanised by cervical dislocation while still anaesthetised. No blood samples were taken during the µPET/MRI experiment.
Murine infection and inflammation models
The mice were anaesthetised with isofluorane inhalation and pre-operative intra muscular injection of buprenorphine (Temgesic, 30 µg/ml, 100 µl). A skin area of approx. 1.5 cm 2 above right scapula was shaved and washed with 70% ethanol. After the ethanol had evaporated, either S. aureus in TSB suspension (5x 10 7 CFU/ml, 100 µl) or turpentine (100%, 100 µl) was injected SC. The hypodermic needle was kept in situ for 5 sec post-injection to prevent retrograde leakage of bacterial suspension. Animals were returned to their cages until the µPET/MRI-scan were conducted 27 ± 2 h later. Humane endpoints were defined as systemic illness, impaired mobility, treatment refractory pain or acute weight loss >15%.
Post-inoculated, the mice in the comparison study had access to buprenorphine 6.0 µg/ml through the drinking water.
µPET/ MRI imaging
In the pilot study, three anesthetised mice with SC infection underwent a 100 min whole body dynamic PET scan immediately after intravenous injection of 3.2 ± 1. A similar setup, as described above, was applied in the SC infection and inflammation comparison study, except for a reduced PET scan time from 100 to 60 min ( Figure 2 ) and the This article is protected by copyright. All rights reserved. The PET scans were evaluated by a nuclear physician. Sites of infection or inflammation were located on the PET images, and the anatomical location in the subcutis was verified on the MRI images. The uptake values of the four hottest voxels on five consecutive images slices were averaged. Two different reference regions were defined (>20 voxels) in the contra-lateral SC region and shoulder muscle (musculus acromiotrapezius), respectively.
Finally, two lesion-to-background ratios were calculated by dividing the average uptake in the infection/inflammation locus by the average uptake in the reference regions.
Post-mortem microbiology and histopathology analyses
Abscesses from the scanned mice (Table 2) This article is protected by copyright. All rights reserved.
dilution (10 µl) was seeded on 5% blood agar plates from SSI Diagnostic (Hillerød, Denmark) and incubated for 24 h at 37 °C before counting CFU.
To characterise the models histologically, tissue representing the SC lesions was removed from selected mice as shown in Table 2 . Tissue samples were fixed in 3.7% neutral buffered formaldehyde for several days, dehydrated, embedded in paraffin wax, cut in 3 µm thick sections, mounted on glass slides, stained with haematoxylin and eosin, and cover slipped according to standard procedures. Table 3 shows the experimental setup for the in vitro binding evaluation of the custom synthesised TAMRA-K-A9, which was performed after the mice pilot infection study of 100 µg (53 nmol) of TAMRA-K-A9 was dissolved in 3% MPBS (1 ml) and the cells in the fluorescence sample vials were re-suspended in this 0.05 mM TAMRA-K-A9 solution (100 µl), while the cells in the control sample vials were re-suspended in 3% MPBS (100 µl).
Morphological binding study
All vials were incubated in the dark for 1 h at room temperature. The cells were subsequently
washed once in 0.1% Tween-20 in PBS and twice in PBS and stored on ice until microscopy.
The membrane-impermeable DNA-binding stain, TOTO®-1, was added to selected vials in a working concentration of 0.001 mM (Table 3) . This was performed to identify if TAMRA-K-A9 preferentially bound to (dead) cells with a permeable membrane, indicating an intracellular target. All samples were visualised on a Zeiss Axiovert 200 M epifluorescence microscope (Göttingen, Germany), using a filter set 43 for TAMRA-K-A9 and filter set 10
for TOTO®-1.
Results and discussion
Radiochemistry
The initial gallium-68 labelling method (Section 2.3.1) yielded 928 ± 70 MBq [ 68 Ga]Ga-DOTA-K-A9 in >91% radiochemical purity with a molar activity of 27 ± 2.0 GBq/µmol at end of synthesis, and a stability of 2 h in the product formulation (pH 3.9 -4.1). In this method, the HEPES is necessary in the product formulation where it acts as radical scavenger 22, 23 to prevent radiolysis of the radio-peptide. In a previous evaluation of the A9
68 Ga-labelling, the use of HEPES aq. solutions lower than 0.1 M, resulted in a slightly improved radiochemical purity, potentially due to reduced [ 68 Ga]Ga-HEPES complexation, while the stability of [ 68 Ga]Ga-DOTA-K-A9 deceased most likely as a consequence of increased radiolysis. 18 The acetone content in the formulation when applying the initial gallium-68 labelling method necessitated extensive dilution prior to the in vivo injection, thus limiting the radioactivity dose given to the mice in the pilot study. Consequently, an optimised preparation method omitting the use of acetone was developed (Section 2.3.2), yielding 371 ± 51 MBq [ 68 Ga]Ga-DOTA-K-A9 in 93 ± 0.9% radiochemical purity with a molar activity of 10 ± 1.4 GBq/µmol at end of synthesis and a stability up to 2 h in the product formulation (pH 5.1-5.7) ( Table 4 ).
Compared to the initial method, the lower yield and thus molar activity of the optimised method is partly due to a lower starting activity of [ 68 Ga]GaCl 3 applied, but also a consequence of radioactivity lost during the product purification step. (Table 5 ).
As seen in the first line of Table 5 , when employing the traditional purification setup: C18
cartridge pre-conditioning with first a 50% EtOH aq. solution then isotonic saline; product rinse by isotonic saline; and final a product elution with first a 50% EtOH aq. solution followed by isotonic saline for formulation, half of the radioactivity remained on the C18-cartridge, including retained [ 68 Ga]Ga-DOTA-K-A9. During the investigation of the similar issue with [ 68 Ga]Ga-DOTA-KGSG-A11 on the C18 cartridge, we observed no improvement in the elution of the radio-peptide when increasing the ethanol concentration in the product elution step. 18 However, the [ 68 Ga]Ga-DOTA-KGSG-A11 peptide was most efficiently eluted when using a 50% EtOH/PBS (2%) solution as eluent and the radio-peptide was subsequently stable in that formulation up to 2 h. Therefore, when evaluating the [
purification we also tried a few different setups with both a 50% EtOH/PBS (2%) solution pH 6.5 and a 50% EtOH/0.1 M HEPES aq. solution pH 6.5 as the eluents ( 
In vivo evaluation
Model characterisation
The murine SC S. aureus infection model with µPET/MRI analysis 24 h post-inoculation was chosen to obtain an acute inflammatory response with incipient abscess formation, containing both dead and viable bacteria. 16, 22 The inflammation model was added to evaluate if the imaging agent was able to distinguish between host tissue inflammatory lesions and bacterial
infection. Of the two methods typically utilised for creating an inflammation model i.e.
injection of heat killed bacteria [23] [24] [25] or turpentine oil, [26] [27] [28] To compare the two lesion types, histopathology and microbiology analyses were performed post-mortem (Table 2 ). Biopsies from 6 turpentine and 3 S. aureus inoculated mice were examined histologically. Various tissue elements, e.g. fatty tissue (white and occasionally brown), sweat glands, striated muscle fibres, lymph nodes, and occasionally skin (epidermis and dermis), were present, often in irregular arrangement, due to multi-purpose use of biopsies ( Table 2 Table 2 .
This was most likely due to the combination of heterogeneous bacterial distribution and division of the abscess tissue for both histopathology and microbiology analyses. To avoid this potential problem all other tissue samples from the µPET scanned S. aureus infection mice solely went to microbiology analysis, while two additional mice (No. 16 and 17) were applied to histologically characterise the infection model ( Table 2 ). The microbiological analysis confirmed the aseptic environment in the turpentine inflammation model with no
CFU grown from the lesions, while in the S. aureus infection model all animals had a clinical
distinct abscess formation and all but one of the abscesses contained viable bacteria with an average bacterial load of 6.1 ± 1.1 log CFU (Table 2 ).
Excretion
In the previously reported in vitro and in vivo studies, [ 68 Ga]Ga-DOTA-K-A9 showed a preserved binding towards S. aureus after gallium-68 labelling and desirable biodistribution features, although it showed a relatively fast metabolic degradation in vivo; with 40% of the remaining radioactivity in the blood after 15 min corresponding to [ 68 Ga]Ga-DOTA-K-A9. 18 In this study the µPET scans of the mice, no physiological accumulation of [ 68 Ga]Ga-DOTA-K-A9 was observed in gastrointestinal system, including biliary duct, gall bladder, or intestine. Thus, the radiolabelled peptide seemed to be solely excreted by the urinary system.
Furthermore, when compared to the [ 18 F]FDG no physiological accumulation was seen in the bowel and heart. Table 6 shows the radioactivity distribution in the urinary system based on the time-activity curves generated from the dynamic [ 68 Ga]Ga-DOTA-K-A9 µPET scan ( Figure 4 ). The accumulation in the kidneys peaked after 2.5 min with 8.1% ± 0.7% of the injected dose located in one kidney after which the activity decreases. Excretion to the urine was fast with 55.9% ± 4.1% of the whole body activity being in the urinary bladder 15 min post-injection. After 60 min 84.5% ± 1.2% of the activity on the PET image was found in the urinary bladder, with the remaining accumulation primarily being located in the kidneys and the infectious and inflammatory foci.
Infection and inflammation binding study
The results of the µPET/MRI experiments of [ However, the lysed material from bacteria and host tissue cells would need to be locally present in large excess to avoid blocking by unlabelled A9 peptide.
In vitro evaluation
The A9 peptide was originally selected by phage-display towards a S. aureus biofilm, but it was not evident to what extent the binding was occurring towards viable or dead bacteria or even the biofilm matrix; the imaging probe [ 68 Ga]Ga-DOTA-K-A9 was, however, subsequently confirmed to bind to both Gram-positive and negative bacteria in vitro. 18 That previously reported experiment was performed on bacteria grown overnight, but as no subsequent microbiological analyses were performed to confirm the viability of the bacteria, it was not known if the observed binding necessitated living bacteria. To clarify this, the binding of the fluorescence analogue TAMRA-K-A9 was evaluated in vitro towards
S. aureus and two other bacterial strains often associated with prosthesis related infections (Table 3) to investigate if the accumulation observed in the murine infections was selective to viable or dead bacteria. However, only few cells in fresh cultures bound the probe ( Figure   8A , 8D, and 8G). This led us to hypothesise that the target was intracellular and therefore only accessible in cells with a compromised membrane. The membrane-impermeable DNA stain TOTO®-1 was therefore combined with TAMRA-K-A9 to assess membrane integrity, and we confirmed that TAMRA-K-A9 only bound to cells with a compromised membrane ( Figure 8C, 8F) . To further corroborate this conclusion, we evaluated the binding of TAMRA-K-A9 in samples of dead bacteria and confirmed that nearly all bacteria in these samples bound the probe ( Figure 8B , 8E, and 8H). Additionally, the binding was not confined to S. aureus but occurred with all the bacterial species tested (Table 3) . Altogether, the results indicated that TAMRA-K-A9 binds to an intracellular epitope in dead bacteria with permeable membranes, and that the epitope were present in all bacterial species tested.
Although, both [ 68 Ga]Ga-DOTA-K-A9 ( Figure 1A ) and TAMRA-K-A9 ( Figure 1B ) are based on the same binding pharmacophore, i.e. the A9 peptide, it cannot be completely disregarded that the individual imaging moiety could somehow influence their affinity differently. However, as the A9 peptide was initially selected towards a S. aureus biofilm, i.e. aggregated viable and dead bacteria embedded in self-produced matrix, the identified affinity of the peptide towards an intracellular epitope in dead bacteria is explicable.
Conclusion
The In the continued search of potential infection-specific PET tracers we still regard the selection process by phage-display as a valuable tool to identify peptides with a selective binding affinity to bacterial components. n/a n/a n/a n/a n/a n/a 7. This article is protected by copyright. All rights reserved. 
